Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 1800

Next Previous
Drug Profile

INO 1800

Alternative Names: INO-1800; INO-1800 SynCon® immunotherapy; RG-7944

Latest Information Update: 27 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 28 Mar 2020 No recent reports of development identified for phase-I development in Hepatitis-B in Australia, USA, Hong Kong, Puerto Rico, Philippines, Singapore, Taiwan, Thailand, New Zealand (IM)
  • 01 May 2018 Inovio Pharmaceuticals completes a phase I trial in Hepatitis B in Thailand, Taiwan, Philippines, Singapore, Puerto Rico, USA, Hong Kong, Australia (IM) (NCT02431312)
  • 11 Apr 2018 INO 1800 is available for licensing as of 14 Mar 2018. https://www.inovio.com/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top